Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes

By Z. Younossi, Aaron B Koenig, Dinan Abdelatif, Yousef Fazel, L. Henry, M. Wymer. Hepatology, 2016

9,590 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/1ddcffa51dd35da666bf8c306bf7cdb7ebf69a58

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Z. Younossi
2. G. Targher
3. M. Rinella
4. Gerald I. Shulman
5. R. Loomba
6. Christopher D. Byrne
7. S. Friedman
8. K. Cusi

In Epidemiology

1. Z. Younossi
2. G. Targher
3. M. Rinella
4. K. Cusi
5. Christopher D. Byrne
6. A. Sanyal
7. Gerald I. Shulman
8. R. Loomba

In Pathology and Forensic Medicine

1. Shira Zelber-Sagi
2. Z. Younossi
3. A. Sanyal
4. M. Rinella
5. K. Cusi
6. Christopher D. Byrne
7. E. Brunt
8. R. Loomba

Citations in the corpus

• Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. (2019, background): “Thus, it is verifying that obese constitute a high proportion of NAFLD patients [58].”
• Treatment of NAFLD with diet, physical activity and exercise. (2017, background): “%) than in the low fat high carbohydrate diet (about 5%), despite a stable weight in both groups.43,44 Importantly, the Mediterranean diet is also characterised by reduced carbohydrate intake (40% of the calories vs. 50–60% in a typical low fat diet), especially reduced sugars and refined carbohydra”
• Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis (2019, background): “48%.(9) Given the paucity of data and the need to collect additional information about NAFLD, a member of the Global Forum sent surveys to 37 medical providers in 21 African and Middle Eastern countries.”
• The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (2018, background): “56), respectively.((16)) The most important histological feature of NAFLD associated with long-term mortality is fibrosis; specifically, zone 3 sinusoidal fibrosis plus periportal fibrosis (stage 2) to advanced (bridging fibrosis [stage 3] or cirrhosis [stage 4]).”
• Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications (2019, background): “NAFLD is the most frequent chronic liver disorder in the general population [142].”
• Global incidence and prevalence of nonalcoholic fatty liver disease (2022, neutral): “01 per 1000 person-years in Israel(9).”
• Current and future pharmacological therapies for NAFLD/NASH (2017, background): “One-fourth of the adult population is now suffering from NAFLD worldwide [1, 2].”
• Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review (2023, background): “18 While CVD is the leading cause of mortality in patients with MASLD, those with more severe liver fibrosis are at increased risk of liver-related mortality, with the risk increasing exponentially with fibrosis stage.”